Global Bioenergies
D
news
her
equity financing line with Kepler Cheuvreux
to accompany his dice
industrial deployment
Évry
,
the
11
nov
ember
202
2
Global Bioenergies announces today the renewal of its equity financing line with Kepler Cheuvreux, a leading European financial services company acting as ISP
1
as part of a firm commitment. This financing solution with Kepler Cheuvreux has already proven its worth at Global Bioenergies: the two-year contract signed in August 2020 has raised 13.6 million euros, and over the same period the valuation of Global Bioenergies has doubled. .
This operation aims to strengthen the financial structure of the company and the funds obtained will contribute in particular to the pre-financing of the production of Isonaturane
®
12 from the new sector known as “Horizon 2” and the completion of engineering studies for the Horizon 3 plant with a capacity of 2,000 tonnes per year, the construction of which will be financed via a dedicated project company in 2023. This operation was implemented in accordance with the 12
th
resolution of the general meeting of shareholders of June 18, 2021.
In accordance with the terms of the agreement, Kepler Cheuvreux has undertaken to subscribe on its own initiative to a maximum of 2,490,000 shares, representing an indicative issue amount of 11 million euros.
2
over a maximum period of 24 months, subject to the contractual conditions being met. The shares will be issued on the basis of an average share price weighted by volumes over the two trading days preceding each issue, less a maximum discount of 5.0%. These conditions allow Kepler Cheuvreux, acting as a financial intermediary, to guarantee the subscription of the shares over the contractual period.
Global Bioenergies retains the ability to suspend or terminate this agreement at any time.
Assuming that this line of financing is used in full, a shareholder holding 1.00% of the capital of Global Bioenergies before its establishment would see his stake drop to 0.86%.
3
capital on a non-diluted basis.
The number of shares issued under this agreement and admitted to trading will be the subject of a monthly communication on the Global Bioenergies website.
This issue does not give rise to the establishment of a prospectus subject to the approval of the AMF.
Samuel Dubruque, Administrative and Financial Director of Global Bioenergies, comments: “The Company is now engaged in commercial production and aims by the end of 2023 to produce three batches of several tons of Isonaturane
®
12 each intended for major players in make-up. At the same time, a project company is being created for the Horizon 3 plant, which will be larger, integrated, and will allow production at a cost compatible with the vast markets of dermocosmetics and hair care. In this very active period, a financing line such as the one renewed today with our partner Kepler Cheuvreux will reinforce, in a flexible and modular way, the available cash (7.3 million euros to date), and will complete the range financing tools necessary for our development. »
About GLOBAL BIOENERGIES
Global Bioenergies converts plant resources into compounds used in cosmetics as well as in the fields of energy and materials. After having launched in 2021 the first long-lasting and natural make-up brand LAST
®
Global Bioenergies now markets Isonaturane
®
12, its key ingredient, to major cosmetics players in order to improve the naturalness of their formulations and their environmental footprint. Ultimately, Global Bioenergies has the prospect of reducing CO emissions
2
air and road transport to help limit global warming. Global Bioenergies is listed on Euronext Growth in Paris (FR0011052257 – ALGBE).
Receive information directly from Global Bioenergies by subscribing to
www.global-bioenergies.com
Follow us on LinkedIn:
Global Bioenergies
contacts
1 Investment Services Provider. Kepler Cheuvreux is authorized and controlled in France by the Autorité de Contrôle Prudentiel and the Autorité des Marchés Financiers
2 On the indicative basis of the weighted average of the prices of the last ten sessions of the share, potential and not guaranteed amount
3 Based on the 14,865,693 shares making up the share capital as of October 31, 2022
Attachment
Global Bioenergies renews its equity financing line with Kepler Cheuvreux to support its industrial deployment